Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Zoomed Almost 10% Higher Today

By Eric Volkman – Aug 13, 2021 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company notched beats on both trailing and anticipated revenue and earnings.

What happened

Co-Diagnostics (CODX 0.67%) was an investor-pleasing machine at the tail end of the week. After reporting highly encouraging Q2 earnings after market close on Thursday, the company's stock unsurprisingly leapt by just under 10% the following day.

So what

Co-Diagnostics beat every collective analyst estimate for its most important metrics during the quarter. The company, which has risen to prominence even among non-healthcare investors because of its COVID-19 diagnostic products, said that its revenue was $27.4 million. That was nearly 14% higher on a year-over-year basis, and easily topped the average prognosticator forecast of almost $20.8 million.

A smiling doctor making a consultation.

Image source: Getty Images.

On the other hand, net income saw a decline, to $9.8 million from the year-ago figure of $15 million. Yet at $0.33 per share, the former was well above the $0.22 average analyst estimate.

In its earnings release, Co-Diagnostics quoted CEO Dwight Egan as saying that the revenue improvement was due in no small measure to success in "cultivating distributor relationships throughout the United States and abroad."

As for the future, he added that "we are well-positioned to maintain our trajectory of growth as our significant investments in talent and [research and development] continue to yield positive results."

Now what

Co-Diagnostics also proffered guidance for its current quarter. The company believes revenue will land in the $23 million to $25 million range, with per-share net earnings coming in at $0.19 to $0.22. Like in the trailing quarter, both ranges topped the average analyst projections ($18.1 million for revenue, and $0.18 per share for net earnings).

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$3.01 (0.67%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.